Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 90

1.

Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Non-Small Cell Lung Carcinoma Patients: the ROSING Study.

Conde E, Hernandez S, Martinez R, Angulo B, De Castro J, Collazo-Lorduy A, Jimenez B, Muriel A, Mate JL, Moran T, Aranda I, Massuti B, Rojo F, Domine M, Sansano I, Garcia F, Felip E, Mancheño N, Juan O, Sanz J, Gonzalez-Larriba JL, Atienza-Cuevas L, Arriola-Arellano E, Abdulkader I, Garcia-Gonzalez J, Camacho C, Rodriguez-Abreu D, Teixido C, Reguart N, Gonzalez-Piñeiro A, Lazaro-Quintela M, Lozano MD, Gurpide A, Gomez-Roman J, Lopez-Brea M, Pijuan L, Salido M, Arriola E, Company A, Insa A, Esteban-Rodriguez I, Saiz M, Azkona E, Alvarez R, Artal A, Plaza ML, Aguiar D, Enguita AB, Benito A, Paz-Ares L, Garrido P, Lopez-Rios F.

J Thorac Oncol. 2019 Jul 23. pii: S1556-0864(19)30562-3. doi: 10.1016/j.jtho.2019.07.005. [Epub ahead of print]

2.

Immune-Related Adverse Events and Outcomes in Patients with Advanced Non-Small Cell Lung Cancer: A Predictive Marker of Efficacy?

Remon J, Reguart N, Auclin E, Besse B.

J Thorac Oncol. 2019 Jun;14(6):963-967. doi: 10.1016/j.jtho.2019.02.031. Epub 2019 Apr 23. No abstract available.

PMID:
31027971
3.

Clinical Benefit From BRAF/MEK Inhibition in a Double Non-V600E BRAF Mutant Lung Adenocarcinoma: A Case Report.

Reyes R, Mayo-de-Las-Casas C, Teixidó C, Cabrera C, Marín E, Vollmer I, Jares P, Garzón M, Molina-Vila MÁ, Reguart N.

Clin Lung Cancer. 2019 May;20(3):e219-e223. doi: 10.1016/j.cllc.2019.02.022. Epub 2019 Mar 4. No abstract available.

PMID:
30926357
4.

Next-generation Sequencing for ALK and ROS1 Rearrangement Detection in Patients With Non-small-cell Lung Cancer: Implications of FISH-positive Patterns.

Clavé S, Rodon N, Pijuan L, Díaz O, Lorenzo M, Rocha P, Taus Á, Blanco R, Bosch-Barrera J, Reguart N, de la Torre N, Oliveras G, Espinet B, Bellosillo B, Puig X, Arriola E, Salido M.

Clin Lung Cancer. 2019 Jul;20(4):e421-e429. doi: 10.1016/j.cllc.2019.02.008. Epub 2019 Feb 26.

PMID:
30898567
5.

Ocular surface adverse events of systemic epidermal growth factor receptor inhibitors (EGFRi): A prospective trial.

Saint-Jean A, Reguart N, Eixarch A, Adán A, Castellà C, Sánchez-Dalmau B, Sainz-de-la-Maza M.

J Fr Ophtalmol. 2018 Dec;41(10):955-962. doi: 10.1016/j.jfo.2018.07.005. Epub 2018 Nov 23.

PMID:
30473235
6.

SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018).

Majem M, Juan O, Insa A, Reguart N, Trigo JM, Carcereny E, García-Campelo R, García Y, Guirado M, Provencio M.

Clin Transl Oncol. 2019 Jan;21(1):3-17. doi: 10.1007/s12094-018-1978-1. Epub 2018 Nov 17.

7.

Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?

Remon J, Hendriks LE, Cabrera C, Reguart N, Besse B.

Cancer Treat Rev. 2018 Dec;71:47-58. doi: 10.1016/j.ctrv.2018.10.006. Epub 2018 Oct 15. Review.

PMID:
30359792
8.

EGFR Amplification and Sensitizing Mutations Correlate with Survival in Lung Adenocarcinoma Patients Treated with Erlotinib (MutP-CLICaP).

Ruiz-Patiño A, Castro CD, Ricaurte LM, Cardona AF, Rojas L, Zatarain-Barrón ZL, Wills B, Reguart N, Carranza H, Vargas C, Otero J, Corrales L, Martín C, Archila P, Rodriguez J, Avila J, Bravo M, Pino LE, Rosell R, Arrieta O; Latin-American Consortium for the Investigation of Lung Cancer (CLICaP).

Target Oncol. 2018 Oct;13(5):621-629. doi: 10.1007/s11523-018-0594-x.

PMID:
30284706
9.

Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types.

Paré L, Pascual T, Seguí E, Teixidó C, Gonzalez-Cao M, Galván P, Rodríguez A, González B, Cuatrecasas M, Pineda E, Torné A, Crespo G, Martin-Algarra S, Pérez-Ruiz E, Reig Ò, Viladot M, Font C, Adamo B, Vidal M, Gaba L, Muñoz M, Victoria I, Ruiz G, Viñolas N, Mellado B, Maurel J, Garcia-Corbacho J, Molina-Vila MÁ, Juan M, Llovet JM, Reguart N, Arance A, Prat A.

Ann Oncol. 2018 Oct 1;29(10):2121-2128. doi: 10.1093/annonc/mdy335.

PMID:
30165419
10.

Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis.

Duruisseaux M, Martínez-Cardús A, Calleja-Cervantes ME, Moran S, Castro de Moura M, Davalos V, Piñeyro D, Sanchez-Cespedes M, Girard N, Brevet M, Giroux-Leprieur E, Dumenil C, Pradotto M, Bironzo P, Capelletto E, Novello S, Cortot A, Copin MC, Karachaliou N, Gonzalez-Cao M, Peralta S, Montuenga LM, Gil-Bazo I, Baraibar I, Lozano MD, Varela M, Ruffinelli JC, Palmero R, Nadal E, Moran T, Perez L, Ramos I, Xiao Q, Fernandez AF, Fraga MF, Gut M, Gut I, Teixidó C, Vilariño N, Prat A, Reguart N, Benito A, Garrido P, Barragan I, Emile JF, Rosell R, Brambilla E, Esteller M.

Lancet Respir Med. 2018 Oct;6(10):771-781. doi: 10.1016/S2213-2600(18)30284-4. Epub 2018 Aug 9.

11.

Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients.

Remon J, Mezquita L, Corral J, Vilariño N, Reguart N.

J Thorac Dis. 2018 May;10(Suppl 13):S1516-S1533. doi: 10.21037/jtd.2017.12.52. Review.

12.

PD-L1 expression testing in non-small cell lung cancer.

Teixidó C, Vilariño N, Reyes R, Reguart N.

Ther Adv Med Oncol. 2018 Apr 11;10:1758835918763493. doi: 10.1177/1758835918763493. eCollection 2018. Review.

13.

Immune checkpoint inhibitors in non-small cell lung cancer (NSCLC): Approaches on special subgroups and unresolved burning questions.

Remon J, Vilariño N, Reguart N.

Cancer Treat Rev. 2018 Mar;64:21-29. doi: 10.1016/j.ctrv.2018.02.002. Epub 2018 Feb 8. Review.

PMID:
29454155
14.

Survival Outcomes According to TIMP1 and EGFR Expression in Heavily Treated Patients with Advanced Non-small Cell Lung Cancer who Received Biweekly Irinotecan Plus Bevacizumab.

Wills B, Cardona AF, Rojas L, Ruiz-Patiño A, Arrieta O, Reguart N, Carranza H, Vargas C, Otero J, Corrales L, Martín C, Cuello M, Pino LE, Rolfo C, Rosell R, Zatarain-Barrón ZL; Latin-American Consortium for the Investigation of Lung Cancer (CLICaP).

Anticancer Res. 2017 Nov;37(11):6429-6436.

PMID:
29061829
15.

Large scale, prospective screening of EGFR mutations in the blood of advanced NSCLC patients to guide treatment decisions.

Mayo-de-Las-Casas C, Jordana-Ariza N, Garzón-Ibañez M, Balada-Bel A, Bertrán-Alamillo J, Viteri-Ramírez S, Reguart N, Muñoz-Quintana MA, Lianes-Barragan P, Camps C, Jantús E, Remon-Massip J, Calabuig S, Aguiar D, Gil ML, Viñolas N, Santos-Rodríguez AK, Majem M, García-Peláez B, Villatoro S, Pérez-Rosado A, Monasterio JC, Ovalle E, Catalán MJ, Campos R, Morales-Espinosa D, Martínez-Bueno A, González-Cao M, González X, Moya-Horno I, Sosa AE, Karachaliou N, Rosell R, Molina-Vila MA.

Ann Oncol. 2017 Sep 1;28(9):2248-2255. doi: 10.1093/annonc/mdx288.

PMID:
28911086
16.

Nintedanib selectively inhibits the activation and tumour-promoting effects of fibroblasts from lung adenocarcinoma patients.

Gabasa M, Ikemori R, Hilberg F, Reguart N, Alcaraz J.

Br J Cancer. 2017 Oct 10;117(8):1128-1138. doi: 10.1038/bjc.2017.270. Epub 2017 Sep 12.

17.

A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib.

Moran T, Palmero R, Provencio M, Insa A, Majem M, Reguart N, Bosch-Barrera J, Isla D, Costa EC, Lee C, Puig M, Kraemer S, Schnell D, Rosell R.

Lung Cancer. 2017 Jun;108:154-160. doi: 10.1016/j.lungcan.2017.03.009. Epub 2017 Mar 22.

PMID:
28625629
18.

Acquired Resistance to Erlotinib in EGFR Mutation-Positive Lung Adenocarcinoma among Hispanics (CLICaP).

Cardona AF, Arrieta O, Zapata MI, Rojas L, Wills B, Reguart N, Karachaliou N, Carranza H, Vargas C, Otero J, Archila P, Martín C, Corrales L, Cuello M, Ortiz C, Pino LE, Rosell R, Zatarain-Barrón ZL; CLICaP.

Target Oncol. 2017 Aug;12(4):513-523. doi: 10.1007/s11523-017-0497-2.

PMID:
28620690
19.

Successful Treatment with Gefitinib in Advanced Non-Small Cell Lung Cancer after Acquired Resistance to Osimertinib.

Chic N, Mayo-de-Las-Casas C, Reguart N.

J Thorac Oncol. 2017 Jun;12(6):e78-e80. doi: 10.1016/j.jtho.2017.02.014. No abstract available.

20.

Tyrosine kinase inhibitor combination therapy in first-line treatment of non-small-cell lung cancer: systematic review and network meta-analysis.

Batson S, Mitchell SA, Windisch R, Damonte E, Munk VC, Reguart N.

Onco Targets Ther. 2017 May 5;10:2473-2482. doi: 10.2147/OTT.S134382. eCollection 2017.

Supplemental Content

Loading ...
Support Center